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Genetically engineered two-
warhead evasins provide a method 
to achieve precision targeting 
of disease-relevant chemokine 
subsets
Yara Alenazi1, Kamayani Singh1, Graham Davies1, James R. O. Eaton1,2, Philip Elders  1, 
Akane Kawamura  1,2 & Shoumo Bhattacharya  1
Both CC and CXC-class chemokines drive inflammatory disease. Tick salivary chemokine-binding 
proteins (CKBPs), or evasins, specifically bind subsets of CC- or CXC-chemokines, and could precisely 
target disease-relevant chemokines. Here we have used yeast surface display to identify two tick 
evasins: a CC-CKBP, P1243 from Amblyomma americanum and a CXC-CKBP, P1156 from Ixodes ricinus. 
P1243 binds 11 CC-chemokines with Kd < 10 nM, and 10 CC-chemokines with Kd between 10 and 100 nM. 
P1156 binds two ELR + CXC-chemokines with Kd < 10 nM, and four ELR + CXC-chemokines with Kd 
between 10 and 100 nM. Both CKBPs neutralize chemokine activity with IC50 < 10 nM in cell migration 
assays. As both CC- and CXC-CKBP activities are desirable in a single agent, we have engineered “two-
warhead” CKBPs to create single agents that bind and neutralize subsets of CC and CXC chemokines. 
These results show that tick evasins can be linked to create non-natural proteins that target subsets of 
CC and CXC chemokines. We suggest that “two-warhead” evasins, designed by matching the activities 
of parental evasins to CC and CXC chemokines expressed in disease, would achieve precision targeting 
of inflammatory disease-relevant chemokines by a single agent.
The 47 structurally related secreted proteins that form the chemokine family differ in the spacing of cysteine 
residues at the N-terminus, and based on this, are classified as CC, CXC, CX3C or XC1. Of these, the 27 CC and 
17 CXC chemokines1 form the majority. Multiple CC and CXC chemokines are typically expressed in tissues 
affected in inflammatory disease2. The combinatorial effects of these chemokines are responsible for the recruit-
ment of innate and adaptive immune cells including monocytes, neutrophils, eosinophils, and lymphocytes to 
sites of inflammation3–5. The synergistic effects between certain CC and CXC chemokines are well documented, 
for instance, in monocyte, lymphocyte and neutrophil migration (reviewed in6), and the functional importance 
of certain CC-CXC chemokine interactions has recently been demonstrated7. The chemokine network has 
been difficult to therapeutically target using monovalent agents such as monoclonal antibodies or small mol-
ecules8,9. Mechanisms underlying the robustness of the network include expression of multiple chemokines in 
tissues affected by inflammatory disease, the ability of chemokines to interact with several chemokine receptors, 
expression of multiple receptor types on leukocytes and immune cells10, synergy and interactions between dif-
ferent chemokines6,7, and feed-forward loops where inflammatory cells recruited to diseased tissue secrete more 
chemokines, thereby amplifying the inflammatory response11.
A number of pathogens and parasitic organisms, including viruses, helminths and ticks, produce structur-
ally unrelated chemokine binding proteins (CKBPs) that target multiple chemokines (reviewed in9,12). Viral and 
helminth CKBPs studied to date, with the exceptions of R1713 and 35-kDa/vCCI14, typically do not discriminate 
between CC and CXC chemokines12,15–17. Tick CKBPs or evasins, originally identified by Proudfoot et al. from 
Rhipicephalus sanguineus18, fall into two structurally unrelated classes that do discriminate between CC and CXC 
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chemokines, and moreover, are also selective in their binding within either chemokine class. Evasins 1 and 4 
solely bind distinctive subsets of CC chemokines, whereas evasin 3 binds only a subset of CXC chemokines. The 
convergent evolution of structurally unrelated peptides in diverse organisms that target the multiple nodes in the 
chemokine network, provides strong evidence that such one-to-many targeting is an effective strategy to disrupt 
chemokine-driven inflammation. Supporting this idea, the potential therapeutic efficacy of viral15, helminth16 
and tick9 CKBPs in inflammatory disease provides proof-of-concept of targeting of the chemokine network as a 
therapeutic approach.
The inadvertent targeting of chemokines that are not involved in the disease process by CKBPs could how-
ever increase the likelihood of off-target effects. The preferential binding of tick evasins to limited subsets of CC 
or CXC chemokines could provide a method to precisely target multiple disease-relevant chemokines without 
unnecessarily affecting other chemokines. To achieve this there is a great need to identify further tick CKBPs 
that bind different subsets of CC and CXC chemokines. Putative evasins have been identified in a variety of 
tick species using bioinformatic analyses of salivary transcriptome data19–21. To rapidly identify tick CKBPs that 
bind chemokines with high-affinity, we screened yeast surface display libraries, constructed to express puta-
tive tick evasins, with fluorescently labelled chemokines, and cloned 10 further evasins from Rhipicephalus and 
Amblyomma genera22. We also showed that these new evasins bound with high affinity to subsets of CC chemok-
ines that range in number from 8–20 chemokines, and not to CXC chemokines. Similar to evasins 1 and 4, these 
new evasins share eight conserved cysteine residues. A common unifying feature of the these 10 evasins was the 
ability to bind CCL2 and CCL13, properties which were not observed in evasins 1 and 422. Further novel evasins 
that bind CC chemokines were identified more recently from Ixodes, Rhipicephalus and Amblyomma genera by 
Hayward et al.23.
Here we describe the functional properties of two evasins identified by yeast surface display, P1243 from 
Amblyomma americanum (also described in Hayward et al.23 as AAM-02), which is a CC-chemokine binding 
CKBP homologous to previously described CC-CKBPs, and P1156 from Ixodes ricinus, a novel CXC-binding 
CKBP that is homologous to evasin 3. We show that P1243 has a distinctive CC-chemokine-binding specificity, 
binding a large number of CC-chemokines including CCL13, but not binding CCL2. P1156 binds CXCL1 and 
CXCL8 strongly, but in addition binds CXCL2, 3, 5 and 6. The availability of different evasins that target subsets of 
CC and CXC chemokines in a one-to-many fashion provides the opportunity to use them in combination to treat 
inflammatory disease characterized by CC and CXC chemokine expression. The development of such therapeu-
tics is however complicated by performance issues including risks and benefits of each individual agent in a com-
bination24. These considerations prompted us to explore the possibility that the two distinct classes of tick evasins 
could be fused into a single agent. We show here, for the first time, that tick CC- and CXC- CKBPs can be fused 
together into a single entity we term a “two-warhead” evasin that binds subsets of both CC and CXC chemokines.
Results
Screening of a yeast surface display library. We screened a yeast surface display library expressing 352 
putative tick CKBPs22 using fluorescence activated cell sorting (FACS) with biotinylated CC and CXC chemokines 
followed by streptavidin–AlexaFluor (AF)647 to label and sort yeast cells that had bound the chemokine. The 
352 putative CKBPs were cloned as a pool into yeast surface display vectors, with either N-terminus (AGA2) or 
C-terminus (SAG1 or AGA2) surface display tags. The pooled library was transformed into yeast, and cells were 
labelled with biotinylated chemokine and streptavidin-AF647. Labelled cells were sorted by FACS. We used a gate 
determined by omitting the chemokine to identify and recover a population of positive cells (Fig. 1A,C). Positive 
cells recovered in the first round were plated and re-grown, and sorted once again as above to further enrich for 
true positive clones. The sorted cells were plated at low density to enable picking of individual yeast clones. As 
part of our established screening protocol, the individual yeast clones were next re-tested by labelling with the 
biotinylated chemokine used in the screen and streptavidin – Alexa 647, and compared to negative control yeast 
that only expressed the relevant surface display tag (Fig. 1B,D). Consistent with observations from our previous 
studies22, and other yeast display methods25, we noted that a proportion of yeast do not display the protein. 
Library plasmids were recovered from clones that successfully re-tested positive, and were sequenced to identify 
the peptide. Through the screening process we identified two novel evasins, P1243 and P1156. P1243 was identi-
fied in screens that used CCL19 (Fig. 1A,B), and also CCL17, CCL4, CCL15, and CCL18 (data not shown). P1156 
was identified in a screen performed using CXCL8 (Fig. 1C,D).
Sequence analysis of P1243. P1243 has 98 amino acid residues with a predicted molecular weight of 
10.9 kDa, and predicted pI of 6.94. Glycosylation site prediction indicates seven N-glycosylation sites. Alignment 
of P1243 with that of other published CC-chemokine binding tick CKBPs shows that it retains the eight Cys 
residues predicted to form disulfide bonds in evasin 1, and their arrangement is consistent with motif C-x(1
4,17)-C-x(3)-C-x(11,16)-C-x(17,20)-C-x(4)-C-x(4)-C-x(8)-C that we have previously described22 (Fig. 2A). 
Sequence-based phylogeny reveals that P1243 is most closely related to P991 (Fig. 2B), with which it shares 67% 
identity over an alignment length of 93 residues and P985 with which it shares 48% identity over 89 residues. It 
shares only 33% identity with evasin 1, over an alignment length of 62 residues. There is no significant homology 
to evasin 3. The Pro residue in evasin 1 that immediately follows the first Cys and targets the disulfide bond in 
CCL313 is conserved in P1243. The conservation of the Cys residues in P1243 with evasin 1 suggested that they 
could potentially form a similar backbone disulfide bonded architecture. We explored this using homology mod-
elling using the structure of evasin 1 in complex with the chemokine CCL326. The Cys disulfide bond architecture 
observed in evasin 1 is conserved in P1243 (Supplementary Material Fig. S1).
Sequence analysis of P1156. P1156 has 80 amino acid residues, with a predicted molecular weight of 
8.8 kDa, and predicted pI of 4.7. It has two predicted N (at positions 16 and 61) and two predicted O-glycosylation 
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Figure 1. Yeast surface display screens. (A) Fluorescence profiles of tick putative CKBP yeast surface display 
library incubated with streptavidin-AF647 (negative control, left panel)) and with biotinylated CCL19 plus 
streptavidin-AF647, middle panel. The sorting gate (red box) was defined based on the negative control and 
was used to sort CKBP expressing yeast that bound biotinylated CCL19. The positive cells identified in the first 
sort were re-grown as a pool, and sorted once again to further enrich for chemokine binding yeast (right panel), 
and plated at low density to recover single clones. The y-axis shows side scatter and x-axis the fluorescence 
intensity on a log-scale. The proportions of cells within the sorting gate are indicated as a percentage. (B) 
Representative fluorescence profile (red) confirming the binding of a P1243 expressing yeast clone isolated in 
the above screen to biotinylated CCL19 and streptavidin-AF647. The fluorescence profile of control yeast with 
vector expressing the surface display tag alone are shown in blue. Y-axis shows cell count, and x-axis shows the 
fluorescence intensity on a log-scale. Positive cells with fluorescence exceeding that of the control are indicated 
as a percentage. The bar indicates the gate used. (C) Fluorescence profiles as above in (A), but using biotinylated 
CXCL8 plus streptavidin-AF647 as probe. (D) Representative fluorescence profile (red) confirming the binding 
of a P1156 expressing yeast clone isolated in the above screen to biotinylated CXCL8 and streptavidin-AF647. 
The fluorescence profile of control yeast with vector expressing the surface display tag alone are shown in 
blue. Y-axis shows cell count, and x-axis shows the fluorescence intensity on a log-scale. Positive cells with 
fluorescence exceeding that of the control are indicated as a percentage. The bar indicates the gate used.
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sites at positions 63 and 75. It has 30% identity with evasin 3 over an alignment length of 43 residues, but no sig-
nificant homology to evasins 1 or 4. An alignment of P1156 with EVA3_RHISA (evasin 3) is shown in Fig. 2C, 
and shows that it has six Cys residues like evasin 3.
Expression of P1243 and P1156. P1243 was expressed as a secreted protein from mammalian cells essen-
tially as described previously22, and purified using a C-terminal StrepII:His purification tag by Ni-NTA affinity 
followed by size exclusion chromatography. P1243 protein in the size exclusion fractions migrated in a range 
of molecular weights ranging from 20–50 kDa (Fig. 3A). This is significantly greater than the predicted molec-
ular weight of 10.9 kDa, and is consistent with the predicted glycosylation at multiple sites, and also with the 
range of molecular weights observed for other evasins expressed in mammalian cells reported by others and us 
previously22,27. The size exclusion fractions containing protein were pooled for subsequent assays. P1156 was 
expressed and purified (Fig. 4A), as described above for P1243. P1156 protein in the size exclusion column frac-
tions migrated at ~17 kDa, significantly larger than its predicted molecular weight of 8.8 kDa, and again consistent 
with its predicted glycosylation. Fractions 4 and 5 were pooled and used for further assays.
Characterization of P1243. We next assayed the binding of P1243 to a panel of chemokines using biolayer inter-
ferometry28. P1243 was immobilized on the sensor through the C-terminal His tag. An initial cross-binding screening 
assay performed at 300 nM chemokine concentration indicated that P1243 bound a number of CC chemokines, certain 
CXC chemokines, and also CX3CL1 and XCL1 (Supplementary Material Fig. S2, Table S2). Binding affinities (Kd) for 
P1243 were next determined using biolayer interferometry titration studies to chemokines identified as potentially 
binding P1243 in the cross-binding screen. In the titration assay, for several chemokines, binding was only detected 
Figure 2. Analysis of P1243 and P1156. (A) CLUSTAL-W alignment of P1243 together with published CC-
chemokine binding evasins. Protein sequence prefix indicates the identity, and suffix indicate the tick species 
as follows: AMBPA, AMBMA, AMBTR, AMBCA, - Amblyomma parvum, maculatum, triste and cajennense 
respectively, and RHIPU and RHISA – Rhipicephalus pulchellus and sanguineus respectively. Physicochemical 
properties are used to color code amino acid residues. Green arrows indicate the eight conserved Cys residues 
that form disulfide bonds in EVA1_RHISA (evasin 1). (B) Sequence similarity based phylogenetic tree of the 
“C8” CKBPs. (C) CLUSTAL-W alignment of P1156 together with EVA3_RHISA. Protein sequence prefix 
indicates the identity, and suffix indicate the tick species as follows: IXORI – Ixodes ricinus, and RHISA – 
Rhipicephalus sanguineus. Physicochemical properties are used to color code amino acid residues. The green 
arrows indicate the six Cys residues that are conserved in EVA3_RHISA (evasin 3).
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at 300 nM and not at lower concentrations (data not shown). These were XCL1, CX3CL1, CXCL4, CXCL5 CXCL7, 
CXCL9, CXCL12 and CXCL14, and as curve fitting could not be performed, and we interpret these as low affinity 
binding and did not investigate them further. Higher affinity binding was identified for 21 CC chemokines where curve 
fitting could be performed. Example sensorgrams are shown in Fig. 3B, with summary Kd and target residence time 
data shown Fig. 5C. Notably, and in contrast to CC-binding evasins previously identified22,26,29,30, P1243 bound CCL13, 
but did not bind CCL2. We also noted that there was a remarkable variation in target residence time (calculated from 
the off rate) ranging from under one minute for CCL7, to over 240 minutes for CCL23.
Characterization of P1156. We next assayed the binding of P1156 to a panel of chemokines using bio-
layer interferometry as described above. An initial screening assay performed at 300 nM chemokine concentra-
tion indicated that P1156 bound only certain ELR + CXC chemokines and not CC, XC or CX3C chemokines 
(Supplementary Material Fig. S2). Binding affinities (Kd) for P1156 were next determined using biolayer interfer-
ometry titration studies against CXC chemokines that were identified as potential binders in the cross-binding 
screen. P1156 bound a number of closely related human ELR + CXC chemokines, including CXCL1, 2, 3, 5, 6 and 
8. Example sensorgrams are shown in Fig. 4B, with summary Kd and target residence time data shown in Fig. 6.
Development of “two-warhead” evasins. We fused P1243 to P1156 via a flexible GGGGS linker in 
order to create the “two-warhead” evasins P1243:G4S:P1156 and P1156:G4S:P1243 (Fig. 5A). The length of 
the peptide in each case is 183 amino acid residues, with a predicted molecular weight of 20 kDa, and pI of 
5.3. The “two-warhead” evasins were expressed and purified using a C-terminal His tag using Ni-NTA affinity 
purification as described previously for the individual evasins. To confirm that full length proteins were pro-
duced we performed N-terminal sequencing of the expressed proteins. This confirmed that the predicted first 
four residues matched the first four residues observed by N-terminal sequencing in each case (Supplementary 
Material Fig. S6). To confirm the integrity of the C-termini we used western blotting of glycosylated and deglyco-
sylated two-warheads using anti-His antibody (Supplementary Material Fig. S7). This showed that glycosylated 
Figure 3. Characterization of P1243. (A) Colloidal Coomassie stained SDS-polyacrylamide gel showing size 
exclusion column fractions (lanes 2–6) obtained following nickel affinity chromatography for P1243. Molecular 
weight ladder (kDa) is shown in lane 1. The gel image was cropped for clarity and the uncropped image is 
provided in Fig.S5. (B) Biolayer interferometry sensorgrams of P1243 binding to indicated chemokines. Plots 
display wavelength shift (y-axis, nm) versus time (x-axis, seconds). Solid lines indicate collected data, dashed 
lines indicate fitted data.
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P1243:G4S:P1156 and deglycosylated P1156:G4S:P1243 could be detected readily. Surprisingly, deglycosylated 
P1243:G4S:P1156 and glycosylated P1156:G4S:P1243 could not be detected in these experiments. We do not 
have an explanation for this glycosylation-dependent variability except that such immunodetection issues have 
also been noted with other His-tagged recombinant proteins31. However, the purification on Ni-NTA affinity 
column, binding to the biolayer interferometry Ni-NTA sensor, together with the western blot data indicate that 
the C-terminal His-tag was intact. Together these experiments showed that the full-length two-warhead pro-
teins were produced in each case. Analysis of the purified protein fractions showed that they migrated at higher 
molecular weights (between 30–60 kDa) than the expected molecular weight of 20 kDa (Fig. 5B). This is consist-
ent with the predicted glycosylation for P1243 and for P1156. The purified protein fractions obtained for each 
“two-warhead” evasin were pooled for further analysis.
Binding of “two-warhead” evasins to CC and CXC chemokines. We next assayed the binding of the 
“two-warhead” evasins to a panel of CC and CXC chemokines using biolayer interferometry, initially by deter-
mining if they bound at 100 nM chemokine concentration in a cross-binding screen (Supplementary Material Fig. 
S2). This suggested binding to several CC and CXC chemokines. In these studies, we found that P1243:G4S:P1156 
appeared to bind certain chemokines (CXCL4, 7, 12, 13, 14) that were not bound by the parental evasins. In titra-
tion experiments we however found that this binding could not be confirmed (Supplementary Material Fig. S8), 
and did not follow this up further. No appreciable binding could be observed for XC or CX3C chemokines for 
either two-warhead evasin. We next performed titration assays in parallel to compare the binding of the parental 
evasins to the “two-warhead” evasins. The results showed that the “two-warhead” evasins bound several, but not 
all of the chemokines bound by the parental evasins (Figs 5C, 6). The chemokines most affected by the fusion 
were the ones that bound the parental evasin with lower affinity. For instance, the two-warhead evasins did not 
bind CCL1, CCL7, CCL22, CXCL3, CXCL5 or CXCL6, whereas the parental evasins clearly did. We also observed 
that the relative position of the two evasins in the construction affected the binding patterns to some extent. For 
example, P1156:G4S:P1243 bound CCL21 and CXCL2, but P1243:G4S:P1156 did not.
Inhibition of CC chemokine function by individual and “two-warhead” evasins. To explore if indi-
vidual and “two-warhead” evasins would inhibit CC chemokine function, we monitored their effects on the migra-
tion of THP-1 human monocyte cells in response to human CC chemokines in 96 well Boyden chamber assays. We 
determined the effect of titrating in progressively increasing doses of evasins at the EC80 dose of each chemokine. 
Individual dose-response experiments against CCL5 are shown in Fig. 7A–C, from which IC50 data were calculated. 
Summary IC50 data for CCL3, CCL3L1 and CCL5, obtained from three biological replicates of such dose-response 
experiments are presented in Fig. 7D–F. Consistent with their ability to bind CCL3, CCL3L1, and CCL5, we found that 
the parental P1243 and “two-warhead” evasins also inhibited the function of these chemokines in a dose-dependent 
manner. Analysis of the summary data (Fig. 7D–F) indicated that the mean IC50 values for P1243, P1243:G4S:P1156, 
and P1156:G4S:P1243 respectively against CCL5 were 8.9E-9, 7.4E-9 and 1.2E-8 M, against CCL3 were 6.5E-9, 1.2E-8, 
and 8.8E-9 M, and against CCL3L1 were 1E-9, 1.7E-9, and 2.2E-9 M. There was no statistically significant difference in 
the ability of either “two-warhead” to inhibit these CC chemokines in comparison to the parental evasin P1243.
Figure 4. Characterization of P1156. (A) Colloidal Coomassie stained SDS-polyacrylamide gel showing size 
exclusion column fractions (lanes 3–6) obtained following nickel affinity chromatography for P1156. Molecular 
weight ladder (kDa) is shown in lane 1. The gel image was cropped for clarity and the uncropped image is 
provided in Fig.S5. (B) Biolayer interferometry sensorgrams of P1156 binding to indicated chemokines. Plots 
display wavelength shift (y-axis, nm) versus time (x-axis, seconds). Solid lines indicate collected data, dashed 
lines indicate fitted data.
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Inhibition of CXC chemokine function by individual and “two-warhead” evasins. We next exam-
ined the effect of the parental P1156 and “two-warhead” evasins on the migration of primary human granulocyte 
cells in response to CXCL8. Individual dose-response experiments are shown in Fig. 8A–C, from which IC50 
data were calculated. Summary IC50 data obtained from three biological replicates of dose-response experiments 
are presented in Fig. 8D. Consistent with their ability to bind CXCL8, we found that the parental P1156 and 
“two-warhead” evasins also inhibited the function of CXCL8 in a dose-dependent manner. Analysis of the sum-
mary data (Fig. 8D) indicated that the mean IC50 values for P1156, P1243:G4S:P1156, and P1156:G4S:P1243 
against CXCL8 were 1.8E-9, 3.8E-8 and 7.5E-9 M respectively. The differences between the evasins were not 
statistically significant.
Discussion
Chemokine-driven inflammation plays a major role in pathogenesis of disease2. These include cardiovascu-
lar disorders such as myocardial infarction32, myocarditis33, atherosclerotic plaque34, and vasculitis35, neu-
rological disorders such as stroke36,37, multiple sclerosis38, and Alzheimer disease37, gastrointestinal disorders 
including inflammatory bowel disease37, pancreatitis39, non-alcoholic steatohepatitis40 and other inflammatory 
Figure 5. Characterization of single and “two-warhead” evasins. (A) Arrangement of the 2-warhead expression 
constructs P1243:G4S:P1156 and P1156:G4S:P1243 (not to scale). P1243 was engineered in-frame with a 
GGGGS (G4S) flexible linker to P1156. The construct was tagged at the C-terminus with a StrepII:8xHis 
purification tag (S2:HIS). (B) Colloidal Coomassie stained SDS-polyacrylamide gels showing size exclusion 
column fractions of P1243:G4S:P1156 (left) and P1156:G4S:P1243 (right) obtained following nickel affinity 
chromatography. Molecular weight ladder (kDa) is indicated in lane 1. The gel images were cropped for clarity 
and the uncropped images are provided in Fig.S5. (C) Binding affinities (Kd, M) and target residence times 
(RT, minutes) of P1243, P1243:G4S:P1156 and P1156:G4S:P1243 to human CC-chemokines using biolayer 
interferometry. High affinity binding is indicated as shades of green, medium affinity as yellow, and low affinity 
as shades of orange. Chemokines are arranged by sequence-similarity based phylogeny. A dash (-) indicates that 
binding was either not detected (CCL2) or that Kd could not be determined. Affinity and target residence time 
in each case was calculated on data obtained at five or more chemokine concentrations.
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Figure 6. Characterization of CXC chemokine binding by single and “two-warhead” evasins. Binding affinities 
(Kd, M) and target residence times (RT, minutes) of P1156, P1243:G4S:P1156 and P1156:G4S:P1243 to human 
CXC-chemokines using biolayer interferometry. High affinity binding is indicated as shades of green, medium 
affinity as yellow, and low affinity as shades of orange. Chemokines are arranged by sequence-similarity based 
phylogeny. A dash (-) indicates that either a titration study was not performed in this experiment (CXCL4, 7, 
9, 10, 11, 12, 13, 14), or that binding could not be detected. Affinity and target residence time in each case was 
calculated on data obtained at five or more chemokine concentrations.
Figure 7. Functional inhibition of CC chemokines by individual and “two-warhead” evasins. (A–C) 
Neutralization of CCL5 induced THP-1 cell migration by P1243, P1243:G4S:P1156, and P1156:G4S:P1243 
respectively. Y-axis shows cell count of THP-1 cells migrating through to the bottom chamber in response to 
EC80 dose of CCL5. In each case, data from a representative experiment are shown as mean ± s.e.m. of three 
technical replicates. X-axis shows CKBP concentration (Log10 Molar). IC50 values (M) indicated in each figure 
were estimated by fitting an agonist response curve with 4 parameters22. (D–F) Summary IC50 data (mean 
± s.e.m., and individual data points from three biological replicates) of the indicated CKBPs against CCL5, 
CCL3 and CCL3L1 respectively. Y-axis shows IC50 (logarithmic scale, M), and x-axis shows each CKBP. CC 
chemokines were assayed using THP-1 cell migration. Each chemokine was assayed at its EC80 dose. There were 
no statistically significant differences between the mean IC50 values in each figure.
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hepatobiliary diseases41–43, lung diseases including idiopathic pulmonary fibrosis44, influenza45,46 and acute lung 
injury47, joint diseases such as rheumatoid arthritis8, and disorders of the skin including psoriasis48 and sclero-
derma44. Many of these disorders are characterized by an initiating insult such as ischemia in myocardial infarc-
tion and stroke, a viral infection in myocarditis and influenza, lipid deposition in the atherosclerotic plaque and 
non-alcoholic steatohepatitis, toxins such as paracetamol or alcohol in liver injury. The initiating insult results in 
the expression of chemokines and cytokines, and the ensuing inflammation can cause further additional damage 
to organs resulting in a vicious cycle of damage and further inflammation.
Typically, in these diseases, multiple CC and CXC class chemokines are expressed, and function synergistically 
to recruit different types of inflammatory cells. Examples of diseases where multiple CC and CXC chemokines are 
expressed include atherosclerosis34, rheumatoid arthritis8, and idiopathic pulmonary fibrosis44. The expression 
of multiple synergistically acting chemokines from different classes in diseased tissues is a factor that contrib-
utes to the difficulty in targeting chemokines using monovalent anti-chemokine therapeutics8,9. A wide range of 
pathogens and parasitic organisms ranging from viruses15, helminths16 and ticks9 produce structurally distinct 
chemokine-binding proteins (CKBPs) that target multiple chemokines. Pre-clinical trials using these CKBPs has 
provided proof-of-concept that targeting of multiple chemokines could be effective in inflammatory disease. In 
particular, tick CKBPs have been shown to be effective in pre-clinical models of arthritis, lung inflammation, 
colitis, pancreatitis, ischemia-reperfusion injury, plaque vulnerability, and psoriasis (reviewed in9).
Putative tick CKBPs have been identified in a variety of tick species using bioinformatic analyses of salivary 
transcriptome data19–21. In an effort to develop a therapeutic armamentarium of tick CKBPs that would provide 
the ability to target only disease-relevant chemokines without unnecessarily targeting irrelevant chemokines we 
have developed a yeast surface display approach to identify high-affinity interactors out of libraries of bioinfor-
matically identified putative tick CKBPs22. Using this approach we identified 10 novel evasins, from Rhipicephalus 
and Amblyomma genera22. We also showed that these new evasins bound specifically to between eight (i.e. 
Figure 8. Functional inhibition of CXC chemokines by individual and “two-warhead” evasins. 
(A–C) Neutralization of CXCL8 induced granulocyte cell migration by P1156, P1243:G4S:P1156 and 
P1156:G4S:P1243 respectively. Y-axis shows cell count of granulocytes migrating through to the bottom 
chamber in response to EC80 dose of CXCL8. Data from a representative experiment are shown as mean ± 
s.e.m. of three technical replicates. X-axis shows CKBP concentration (Log10 Molar). IC50 values (M) indicated 
in each figure were estimated by fitting an agonist response curve with 4 parameters22. (D) Summary IC50 data 
(mean ± s.e.m., and individual data points from three biological replicates) of the indicated CKBPs against 
CXCL8. Y-axis shows IC50 (logarithmic scale, M), and x-axis shows each CKBP. CXCL8 was assayed using 
granulocyte cell migration at its EC80 dose. There were no statistically significant differences between the mean 
IC50 values.
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“narrow spectrum”) to 20 (i.e. “broad-spectrum”) CC chemokines, but not to CXC chemokines. A common 
unifying feature of the these 10 new evasins was their ability to bind CCL2 and CCL13, properties which were not 
observed in evasins 1 and 422. These evasins contain eight cysteine residues that are conserved in evasins 1 and 4. 
Further novel eight cysteine or “C8” evasins that bind CC chemokines were identified more recently from Ixodes, 
Rhipicephalus and Amblyomma genera by Hayward et al.23.
In this study, we have identified and characterized a further C8 CC-CKBP, P1243. This was also recently 
reported and partially characterized by Hayward et al.23 as AAM-02, and shown to bind CCL11, CCL24, 
CCL26, CCL2, and CCL7. Our results indicate that P1243 binds 21 CC chemokines, of which 11 are bound with 
Kd < 10 nM, and so can be regarded as a “broad-spectrum” CC-chemokine inhibitor, akin to EVA4_RHISA29 and 
P99122. However, P1243, unlike P991, does not bind CCL2 at 300 nM, and we were unable to determine a Kd using 
our assay conditions (data not shown). This is consistent with data from Hayward et al.23 who show that the Kd for 
AAM-02 binding to CCL2 is 1000 nM. In comparison to P991, P1243 has a far shorter target residence time for 
chemokines that are bound in common, suggesting that a potential use may be to achieve short-term inhibition 
of the chemokine system, whereas P991 would achieve a longer-term inhibition. Analysis of CC-CKBPs show that 
they all retain the eight cysteine residues that form disulfide bonds in evasin 122. Homology modelling of P1243 
and other CC-CKBPs reported previously by us22 indicates that these Cys residues likely form disulfide bonds, 
and we thus refer to them as “C8” tick CKBPs. Like previously characterized CC-CKBPs, P1243 has multiple pre-
dicted glycosylation sites, and in keeping with this, migrates significantly slower than predicted by the calculated 
molecular weight of the peptide. As glycosylation does not appear to be required for chemokine recognition26, 
it may instead have other functions for instance reducing immunogenicity by creating a “glycan-shield”49,50, or 
improving protein stability51.
In this study, we have also identified a novel CXC-CKBP, P1156, which binds six ELR + CXC class chemok-
ines, CXCL1, 2, 3, 5, 6 and 8, which have, in common, a Glu-Leu-Arg motif immediately preceding the first Cys 
residue, the ability to bind the receptors CXCR1 and/or CXCR2, and neutrophil trafficking activity1. P1156 is 
homologous to EVA3_RHISA30, and like it, binds CXCL1 and CXCL8 strongly. We have subsequently identified 
a number of additional evasins that have six Cys residues that align well with the six Cys residues of evasin 3 and 
bind CXC-chemokines. We therefore refer to these tick CKBPs collectively as “C6” CKBPs. It should be noted 
that the “C6” evasin P1156 described in this study is distinct from those described in Hayward et al.23. Like 
EVA3_RHISA, P1156 is also predicted to be glycosylated, and migrates significantly slower than predicted by the 
calculated molecular weight of the peptide.
The availability of several evasins that bind multiple CC and CXC chemokines provides an opportunity to 
match disease-relevant subsets of both CC and CXC chemokines, and develop novel therapeutics that would not 
target irrelevant chemokines. A disadvantage of tick CKBPs, however, is that their inability to target both CC and 
CXC chemokines would mean that combinations of “C8” CC- and “C6” CXC-CKBPs would need to be used. 
Such combinations of one or more agents require evaluation of the risks and benefits of each agent in the com-
bination24, rendering the development of combination therapeutics more difficult. Inspired by the development 
of bispecific antibodies52, we explored the possibility that the two distinct classes of tick CKBPs could be fused 
into a single “two-warhead” agent. To achieve this, we linked P1243 with P1156 using a GGGGS linker to min-
imize steric hindrance and misfolding. The resultant “two-warhead” CKBPs retain most of the properties of the 
parental CKBPs, and can bind and neutralize subsets of both CC and CXC-chemokines. The mechanism of loss 
of some chemokine binding in the “two-warhead” CKBPs is unclear at present. One possible explanation is steric 
hindrance, and although this was not overcome by swapping the relative positions of P1243 and P1156, it could 
potentially be overcome by adopting longer linkers or other linker types53. A limitation of our current work is that 
we have only shown the effects of the two-warhead evasins in assays that measure chemokine effects on single cell 
types such as monocytes or granulocytes. In future work it would be important to develop in vitro assays that use 
different combinations of white blood cell types, for instance present in whole blood, and a mixture of chemok-
ines, and also validate the two-warhead evasins usng in vivo assays of inflammation.
Applications of a “two-warhead” tick CKBP that binds both a CC chemokine and a CXC chemokine may 
include the therapeutic inhibition of chemokine signalling in any inflammatory disease associated with both 
CC and CXC chemokines. By examination of chemokine expression patterns in disease and the binding char-
acteristics of the two-warhead CKBP P1243:G4S:P1156 reported in this paper, certain exemplar therapeutic 
indications would thus include myocarditis, myocardial infarction, atherosclerosis, vasculitis, idiopathic pul-
monary fibrosis, inflammatory bowel disease and rheumatoid arthritis (Table S1). An alternative approach 
would be to combine a CC chemokine binding evasin with a CXCR1/CXCR2 antagonist such as SCH527123/
diaminocyclobutandione-154, which would block signalling by the neutrophil attracting chemokines blocked by 
P1156. However, as discussed previously, the development of such combination therapeutics is complicated by 
issues involving risks and benefits of each individual agent in a combination24.
In conclusion, we have shown that it is possible to target specific CC- and CXC-chemokine subsets by using a 
single agent that is created by a fusion of a tick CC- and a tick CXC-CKBP. As each tick CC- and CXC-CKBP has 
a remarkably distinctive chemokine binding profile, including narrow and broad-spectrum binding activities, the 
single agent created by fusing the two will also have a unique and distinctive CC and CXC-chemokine binding 
profile. This ability to tailor the chemokine binding profile of a “two-warhead” evasin by selecting parental eva-
sins with appropriate CC and CXC binding activity, may provide a significant advantage over viral or helminth 
CKBPs where such ability to tailor binding properties has not yet been demonstrated. We suggest that novel 
“two-warhead” CKBPs, designed by matching the chemokine-subset binding properties of parental CKBPs to the 
CC and CXC chemokines expressed in a particular inflammatory disease, would achieve precision targeting of 
disease-relevant CC and CXC chemokine subsets by a single agent. We predict that such agents would be useful 
in the therapy of a broad range of inflammatory disease that are characterised by the combinatorial expression of 
CC and CXC chemokines.
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Experimental procedures
Yeast surface display. Yeast surface display was performed exactly as described previously22. Briefly, 
EBY100 yeast transformed with tick transcriptome library plasmids were induced with galactose and labelled 
with biotinylated chemokines (Almac) and streptavidin-AF647, and then sorted using a MoFlo FACS system 
based on a gate defined by a negative control that omitted the chemokine. Cells obtained were regrown, and a 
second round of sorting was performed, following which cells were plated at low dilution to facilitate recovery of 
individual clones. Plasmid inserts from individual clones were amplified by PCR and sequenced to identify the 
insert. Individual yeast clones were also re-tested to confirm chemokine binding by FACS analyses using a 96-well 
ATTUNE NXT system (Life Technologies).
Plasmids. P1243, P1243:G4S:P1156 and P1156:G4S:P1243 expression plasmids were constructed in plasmid 
pHLSec55 using PCR and infusion cloning as described22 and contained a C-terminal G4S linker, a strep II-8xHis 
protein purification tag (GGGGGSGGGGSGGASAWSHPQFEKLEHHHHHHHH56), and an N-terminal ETG 
sequence from pHLSec.The P1156 expression plasmid was constructed using idempotent parts using our labora-
tory’s adaptation of the GoldenGate/GoldenBraid cloning method22. Parts included the CAGGS promoter (from 
GenBank Sequence AB281497), Igk signal peptide57, StrepII:His tag (GGASAWSHPQFEKLEHHHHHHHH, 
pQE-Trisystem, Qiagen), and bovine growth hormone terminator (pcDNA3, Invitrogen). Following signal pep-
tide cleavage the expected sequence at the N-terminus is DGG predicted by SignalP 3.058.
Protein sequence analysis. We used Clustal-W in Megalign Pro (DNAStar version 12.3.1, DNAStar Inc.), 
to construct CKBP sequence alignments and generate a sequence-similarity based phylogenetic tree which was 
exported to FigTree (version 1.4.2, http://tree.bio.ed.ac.uk/software/figtree/). Glycosylation sites were predicted 
using NetNGlyc1.0 (http://www.cbs.dtu.dk/services/NetNGlyc/) and NetOGlyc4.0 (http://www.cbs.dtu.dk/ser-
vices/NetOGlyc/)59. Molecular weight and isoelectric point (pI) of proteins were calculated at ExPASy(http://web.
expasy.org/compute_pi/). We used MUSCLE in Megalign Pro to construct chemokine sequence alignments and 
sequence-similarity based phylogenetic trees. Homology modelling was performed using MODELLER60, within 
PYMOD2.061, using the evasin 1: CCL3 structure 3FPU26 as template. Disulfide bonds were identified using using 
the Protein Interaction Calculator62.
Cell lines. HEK293F cells were a gift from Nicola Burgess-Brown (University of Oxford). THP-1 cells were 
purchased from Sigma. A MycoAlert™ (Lonza) kit was used to confirm freedom from mycoplasma contami-
nation. Cells were functionally authenticated by protein production and chemokine – induced migration for 
HEK293F and THP-1 respectively.
CKBP production. CKBPs were produced as described previously22 from HEK293F cells using Nickel 
charged IMAC Sepharose 6 Fast Flow resin (GE Healthcare), and further purified by size exclusion chromatog-
raphy. Fractions showing absorption at 280 nm were analyzed by electrophoresis on a 12% SDS-PAGE gel, and 
stained with colloidal Coomassie. Yields obtained (mg/L culture supernatant volume) were 10.1 for P1243, 3.6 for 
P1156, 46.4 for P1243:G4S:P1156, and 13.1 for P1156:G4S:1243. N-terminal sequencing of two-warhead proteins 
was performed using Edman degradation at Alta Bioscience, Birmingham.
Deglycosylation. Two-warhead CKBPs were prepared as above except that kifunensine was added to a final 
concentration of 7.5μg/mL following transfection. Purified protein was diluted 1:1 with 40 mM HEPES, 300 mM 
NaCl and 1 mM TCEP, and then treated with PNGaseF (NEB) and EndoF1 (gift from C. Siebold, STRUBI) at 
a ratio of 1:1000 and incubated overnight at 37 °C. Degylcosylated protein was purified by size exclusion chro-
matography. Western blotting was performed using standard protocols63, using a mouse monoclonal anti-His 
primary antibody (R&D Systems) and HRP-tagged goat anti-mouse secondary antibody (Jackson), and Western 
Lightning ECL Pro (Perkin Elmer kit), and imaged on a BioRad ChemiDoc MP system following the manufac-
turer’s instructions.
Biolayer interferometry cross-binding screen. Biolayer interferometry was performed as described 
previously22. Briefly, we used an OctetRed® system using dip and read Ni-NTA biosensors (ForteBio). The assay 
buffer contained 10 mM Na2HPO4, 1.8 mM KH2PO4, 2.7 mM KCl, 500 mM NaCl, 0.1% BSA, 0.002% TWEEN-20, 
pH 7.4. Assay buffer was used to establish the response baseline (180 seconds). The temperature condition (30 °C) 
was recommended by the manufacturer. Purified evasin (His-tagged) was immobilized on the Ni-NTA sensor 
using 1 μM evasin in assay buffer for 500 seconds. The sensor was washed with assay buffer for 60 seconds, and 
then exposed to 300 nM chemokine in assay buffer to record the association phase. As low affinity binders were 
identified by this assay, for the two-warheads we used a 100 nM chemokine concentration for the cross-binding 
screen. The cross-binding screen was performed as a single experiment against all human chemokines with the 
exception of CCL25, CCL26, and CXCL16, where chemokine non-specifically bound to the sensor, and CXCL17, 
CXCL4L1, and XCL2, which were not available from Peprotech. The sensor was exposed to assay buffer to meas-
ure dissociation. The sensor was regenerated as described previously before re-use22. Reference experiments were 
performed by placing a sensor with evasin alone loaded into buffer to account for baseline drift which was then 
subtracted. Data was processed in ForteBio Data Analysis 9 software.
Biolayer interferometry. Titration experiments were carried as described previously22. Briefly, each exper-
iment was performed once with chemokine concentration ranging from 300 nM to 0.4 nM, (except for CXCL2 
where a range of 600 nM to 1.2 nM was used due to issues with data fitting) and using a non-interacting reference 
protein (of s eq ue nce D GG QRNAICRLPPDEGICRASIPRFYFNPAEGKCSFFIYGGCEGNENNFETIEECEKTC
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GEPERPSDFEGADFETGCAPKPQRGFCKGFLDHWFFNVTSGECEAFLYSGCGGNDNNYESKEECEIACKL
TGGASAWSHPQFEKLEHHHHHHHH) to allow for non-specific binding to the sensor. For each titration assay, 
at least five chemokine concentrations were studied. ForteBio Data Analysis 9 software was used to process the 
data and calculate association (kon), dissociation (koff), and affinity (Kd) constant using a one-site binding fit. The 
off-rate (koff, s−1) obtained from biolayer interferometry was used to calculate the target residence time or disso-
ciation half-life as described22,64. For certain chemokine-evasin interactions where a curve fit was not possible, a 
steady state analysis was performed using ForteBio Data Analysis 9 software to obtain the Kd, from the equilib-
rium response, and here koff and kon, and hence target residence times were not calculated. Data with poor curve 
fits (R2 < 0.9) were excluded.
THP-1 cell migration assays. THP-1 monocyte migration assays were performed as described previ-
ously22. Briefly, chemokine (EC80 dose) and evasin (0.006–300 nM doses, in 0.5% fetal bovine serum) were added 
to the bottom chamber of a 96-well transwell migration plate (5 μM pore size, Corning) and incubated for 30 min 
at 37 °C before beginning the cell migration assay by adding 5E5 cells to the top chamber. Three technical rep-
licates for each IC50 determination were analysed in GraphPad Prism fitting an inhibitor response curve with 4 
parameters. The mean IC50 from three biological replicates was then calculated. In control experiments (Fig. S3A) 
we observed that evasins inhibited the small degree of migration induced in vehicle alone controls, we attribute 
this to neutralization of naturally occurring chemokines in serum65.
Granulocyte migration assays. Human granulocyte migration assays (see Supplementary Material Figs S3 
and S4) were performed using 96 well transwell migration plates (3 μM pore size, Corning). Fresh whole blood 
was collected from healthy individuals each day of experiment. To collect granulocytes, red blood cells were 
first depleted, from whole blood, using HetaSep™ (StemCell Technologies) following instructions of the manu-
facturer. All nucleated cells were then collected and any remaining red blood cells lysed using MACS Red Lysis 
Buffer (MACS, Miltenyi Biotec). Cells were counted on a ATTUNE flow cytometer using a forward scatter (FSC) 
versus side scatter (SSC) dot plot. Effective concentrations (EC) EC80 and EC50 for each chemokine was deter-
mined each day, for each batch of blood, in three technical replicates. Chemokines (0–100 nM (Peprotech), in 
150 μl RPMI-1640 + L-glu (2 mM) + 0.5% heat treated fetal bovine serum (all from Sigma) were placed in the 
bottom chamber. Cells (2E5, in 50 μl RPMI- 1640 + L-glu (2 mM) + 0.5% heat treated fetal bovine serum) were 
placed in the top chamber, and incubated at 37 °C, 5% CO2 for one hour. The migration plate was shaken at 850 
r.p.m. for 10 minutes, and media from bottom plate transferred to a U-bottomed 96 well plate. Cells were counted 
on a ATTUNE flow cytometer using a FSC versus SSC dot plot, and data analysed in GraphPad Prism fitting an 
agonist response curve with 4 parameters. IC50 for each evasin was determined in three technical and three bio-
logical replicates using the above system. Chemokine (EC80 dose determined on day of experiment) and evasin 
(0.01 nM-600 nM concentration) were added to the bottom chamber and incubated for 30 min 37 °C, before 
beginning the cell migration assay. Data (three technical replicates for each IC50 determination) were analysed 
in GraphPad Prism fitting an inhibitor response curve with four parameters. The mean IC50 from three biolog-
ical replicates was then calculated. In control experiments (Supplementary Material Fig. S3B) we observed that 
evasins inhibited the small degree of migration induced in vehicle alone controls, we attribute this to neutraliza-
tion of naturally occurring chemokines in serum65. The experiments performed on human blood samples were 
done according to University of Oxford guidelines. Specifically, this study did not require institutional ethical 
approval as the human tissue was being used solely as a reagent to assay evasin activity. Verbal informed consent 
was taken from all volunteers who donated the blood samples. All samples were anonymised before use, and no 
samples were stored. Formal review of the process was obtained from the University of Oxford Medical Sciences 
Interdivisional Research Ethics Committee (MS IDREC).
Statistical analyses. GraphPad Prism was used to calculate summary statistics. Tests of significance were 
calculated using ordinary one-way ANOVA, assuming Gaussian distribution and equal variance, in GraphPad 
Prism, with Tukey’s correction for multiple testing.
Data availability. The authors declare that data supporting this manuscript are available either within the 
manuscript or as Supplementary Information.
Nucleotide accession numbers. JAG91989.1 (P1243) and JAB72437.1 (P1156)
Note added in proof: A further novel C8 evasin that binds CC chemokines was reported by us while this manu-
script was under review66.
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